文献速递慢性肾脏病血液净化与透析

肾脏医疗质量评估:现有质量指标的评价与改进框架

Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery.
PubMed 文献 · J Am Soc Nephrol · 2020-02-13

美国肾脏病学会质量委员会对60项国家肾脏质量指标进行两轮结构化评估,基于重要性、适当性、证据基础、清晰度和可行性标准,发现仅49%指标具有高有效性,多数指标与透析管理相关,而肾脏替代治疗规划和患者报告结局指标严重不足。

要点

  • 仅49%的肾脏质量指标具有高有效性,38%为中等,13%为低有效性。
  • 近半数指标与透析管理相关,肾脏替代规划仅1项,患者报告结局仅2项。
  • 低有效性主要源于归属不清、定义和风险调整不足或与近期证据不一致。

核心结论

  • 不到一半的肾脏疾病质量指标被评为高有效性,其余因归属不清、定义和风险调整不足或与近期证据不一致而存在缺陷。
  • 现有指标中近半数与透析管理相关,而肾脏替代治疗规划和患者报告结局指标分别仅有1项和2项。
  • 建议完善现有指标并开发新指标,以更好地反映肾脏医疗服务的全谱。

研究设计与样本

  • 美国肾脏病学会质量委员会成员从多个肾脏和质量组织汇编了国家肾脏质量指标综合列表。
  • 采用美国内科医师学会标准进行两轮结构化指标评估,标准包括重要性、适当护理、临床证据基础、指标规范清晰度以及可行性和适用性。
  • 共纳入60项质量指标,涵盖CKD预防、CKD进展延缓、CKD管理、晚期CKD与肾脏替代规划、透析管理、广泛措施和患者报告结局指标。

主要发现

  • 60项指标中,7项用于CKD预防,2项用于延缓CKD进展,2项用于CKD管理,1项用于晚期CKD和肾脏替代规划,28项用于透析管理,18项为广泛措施,2项为患者报告结局指标。
  • 基于既定标准,29项(49%)指标具有高有效性,23项(38%)具有中等有效性,8项(13%)具有低有效性。

关键数值与推荐

  • 高有效性指标29项(49%),中等有效性23项(38%),低有效性8项(13%)。

临床怎么用

  • 临床医生和policy maker可参考该评估框架选择高有效性指标进行质量改进。
  • 应优先关注归属清晰、定义明确、风险调整充分且与近期证据一致的指标。
  • 需加强肾脏替代治疗规划和患者报告结局等领域的指标开发与应用。

局限性

  • 评估仅基于美国内科医师学会标准,可能未涵盖所有质量维度。
  • 指标列表来源于多个组织,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leveraging quality metrics can be a powerful approach to identify substantial performance gaps in kidney disease care that affect patient outcomes. However, metrics must be meaningful, evidence-based, attributable, and feasible to improve care delivery. As members of the American Society of Nephrology Quality Committee, we evaluated existing kidney quality metrics and provide a framework for quality measurement to guide clinicians and policy makers. METHODS: We compiled a comprehensive list of national kidney quality metrics from multiple established kidney and quality organizations. To assess the measures' validity, we conducted two rounds of structured metric evaluation, on the basis of the American College of Physicians criteria: importance, appropriate care, clinical evidence base, clarity of measure specifications, and feasibility and applicability. RESULTS: We included 60 quality metrics, including seven for CKD prevention, two for slowing CKD progression, two for CKD management, one for advanced CKD and kidney replacement planning, 28 for dialysis management, 18 for broad measures, and two patient-reported outcome measures. We determined that on the basis of defined criteria, 29 (49%) of the metrics have high validity, 23 (38%) have medium validity, and eight (13%) have low validity. CONCLUSIONS: We rated less than half of kidney disease quality metrics as highly valid; the others fell short because of unclear attribution, inadequate definitions and risk adjustment, or discordance with recent evidence. Nearly half of the metrics were related to dialysis management, compared with only one metric related to kidney replacement planning and two related to patient-reported outcomes. We advocate refining existing measures and developing new metrics that better reflect the spectrum of kidney care delivery.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mendu ML, Tummalapalli SL, Lentine KL, et al. Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery. J Am Soc Nephrol. 2020. PMID: 32054692. doi:10.1681/ASN.2019090869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。